Product
Lotilaner
Aliases
Lotilaner ophthalmic solution, 0.25%, S-Misoxam, TP-03
Name
XDEMVY
INN Name
Lotilaner ophthalmic solution
FDA Approved
Yes
3 clinical trials
1 organization
3 indications
1 document
Indication
BlepharitisIndication
Demodex BlepharitisIndication
RosaceaClinical trial
Randomized Controlled, Multicenter, Double-Masked, Parallel Phase III Trial to Evaluate the Efficacy and Safety of Lotilaner Ophthalmic Solution for the Treatment of Demodex Blepharitis in China With an Open-Label Pharmacokinetics Sub-StudyStatus: Active (not recruiting), Estimated PCD: 2023-09-15
Clinical trial
Randomized Controlled Trial to Evaluate the Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens WearersStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of TP-04 in Participants With Papulopustular RosaceaStatus: Completed, Estimated PCD: 2023-11-13
Document
DailyMed Label: XDEMVYOrganization
Tarsus Pharmaceuticals, Inc.